Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MS drug trial targets chinese patients

NCT ID NCT07483450

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study tests the drug ocrelizumab in 60 Chinese adults with two forms of multiple sclerosis (MS): relapsing MS and primary progressive MS. The goal is to see if it reduces relapses and controls disease activity. Participants receive ocrelizumab infusions, and researchers track relapses, brain scans, and B-cell levels over 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ocrelizumab (OCREVUS)
What this could lead to
If successful, this could confirm that ocrelizumab works well for Chinese MS patients, offering a treatment option to reduce relapses and slow disability progression.
What could go wrong
This is a small, open-label study with no placebo group, so results may not be definitive. Ocrelizumab can increase infection risk and infusion reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of RMS/PPMS in accordance with the revised 2017 McDonald Criteria * EDSS score from 0-5.5 (RMS) or 3.0-6.5 (PPMS), inclusive, at screening and baseline * Documented MRI of brain with abnormalities consistent with MS before screening Exclusion Criteria: * Diagnosis of PPMS or non-active secondary progressive multiple sclerosis (SPMS) (only for RMS cohort) * History of relapsing remitting multiple sclerosis (RRMS) or SPMS at screening (only for PPMS cohort) * Disease duration of more than 10 years in participants with an EDSS ≤ 2.0 at screening (only for RMS cohort) * History of confirmed or suspected progressive multifocal leukoencephalopathy (PML) * Inability to complete an MRI scan or contraindication to Gd administration * Contraindications to mandatory pre-medications (i.e., corticosteroids and antihistamines) * Known presence of other neurologic disorders if they could interfere with the diagnosis of MS or assessments of efficacy and/or safety during the study * Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study * Known history of human immunodeficiency virus (HIV) infection * Lack of peripheral venous access * Previous treatment with B-cell targeted therapies (i.e., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab), unless the last infusion was at least 6 months prior to screening * Positive screening tests for hepatitis B virus (HBV) and/or hepatitis C virus (HCV)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary progressive multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis primary progressive multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary progressive multiple sclerosis Relapsing multiple sclerosis

Contacts and locations

Locations

  • 1st Affiliated Hospital of Shanxi Medical University

    Taiyuan, 030000, China

  • Beijing Hospital of Ministry of Health

    Beijing, 100730, China

  • Inner Mongolia Autonomous Region People's Hospital

    Hohhot, 010011, China

  • Lanzhou University Second Hospital

    Lanzhou, 730030, China

  • Peking Union Medical College Hospital

    Beijing, 100032, China

  • Peking University First Hospital

    Beijing, 100034, China

  • The First Affiliated Hospital of College of Medicine, Zhejiang University

    Hangzhou, 310003, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330209, China

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, 510080, China

  • The First Affiliated Hospital, Chongqing Medical University

    Chongqing, 400016, China

  • The First Hospital of China Medical University

    Shenyang, DUMMY_VALUE, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, 050000, China

  • The Third Affiliated Hospital of Sun Yat-Sen University

    Guangzhou, 510630, China

  • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, 430030, China

  • West China Hospital of Sichuan University

    Chengdu, 610041, China

  • Xiangya Hospital Central South University

    Changsha, 410008, China

  • Xinjiang People Hospital

    Ürümqi, 830000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.